TBUFF (Tribute Pharmaceuticals Canada) 6-Month Share Buyback Ratio : 0.00% (As of Sep. 2015 )

View and export this data going back to . Start your Free Trial

What is Tribute Pharmaceuticals Canada 6-Month Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Tribute Pharmaceuticals Canada's current 6-Month Share Buyback Ratio was 0.00%.

Competitive Comparison of Tribute Pharmaceuticals Canada's 6-Month Share Buyback Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Tribute Pharmaceuticals Canada's 6-Month Share Buyback Ratio, along with its competitors' market caps and 6-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tribute Pharmaceuticals Canada's 6-Month Share Buyback Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tribute Pharmaceuticals Canada's 6-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Tribute Pharmaceuticals Canada's 6-Month Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Tribute Pharmaceuticals Canada 6-Month Share Buyback Ratio Calculation

Tribute Pharmaceuticals Canada's 6-Month Share Buyback Ratio for the quarter that ended in Sep. 2015 is calculated as

6-Month Share Buyback Ratio	=	(Shares Outstanding (EOP) (Mar. 2015 )	-	Shares Outstanding (EOP) (Sep. 2015 ))	/	Shares Outstanding (EOP) (Mar. 2015 )
	=	(99.907	-	126.241)	/	99.907
	=	-26.36%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tribute Pharmaceuticals Canada (OTCPK:TBUFF) 6-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Tribute Pharmaceuticals Canada 6-Month Share Buyback Ratio Related Terms

Tribute Pharmaceuticals Canada Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tribute Pharmaceuticals Canada Inc (OTCPK:TBUFF) » Definitions » 6-Month Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.stellarpharma.com

Tribute Pharmaceuticals Canada Inc was incorporated under the Business Corporations Act (Ontario) on November 14, 1994. The Company is a specialty pharmaceutical company. It conducts acquisition, licensing, development and promotion of healthcare products in Canada. It sells Uracyst and NeoVisc internationally through a number of strategic partnerships. The Company's portfolio of assets includes nine product lines, eight of which are on the market in Canada, including: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, Collatamp G, and MycoVa. The Company markets its products in Canada through its own sales force and currently has licensing agreements for the distribution of select products in over 20 countries, and continues to expand this footprint. It faces product competition from companies marketing competing pharmaceutical products and medical devices in Canada. The Company's operations are or may be subject to various federal, provincial, state and local laws, regulations and recommendations relating to the marketing of products and relationships with treating physicians, data protection, safe working conditions, laboratory and manufacturing practices, the export of products to certain countries and the purchase, storage, movement, use and disposal of hazardous or potentially hazardous substances.

Executives

John M Gregory	director, 10 percent owner
Sj Strategic Investments Llc	10 percent owner
Joan P Gregory	other: Member	340 EDGEMONT AVE., SUITE 500, BRISTOL TN 37620
James M Gregory	other: Member	340 EDGEMONT AVE., SUITE 500, BRISTOL TN 37620
Susan Gregory	other: Member	340 MARTIN LUTHER KING, JR. BLVD, SUITE 200, BRISTOL TN 37620

Tribute Pharmaceuticals Canada Headlines

No Headlines